What Did You See in 2026?
You joined the European hub for proximity-based drug discovery as the 6th TPD & Induced Proximity Summit Europe returned to London. The 2026 summit offers a focused, single-track experience that brought together Europe’s most innovative minds working on targeted protein degradation and proximity-based therapeutics. From antibody-based degraders to molecular glues and stabilizers, the program highlighted real-world applications and clinical momentum.
You expected a dynamic mix of first-in-human data, biology-first strategies, and deep-dive workshops designed to tackle challenges in oral bioavailability, PK/PD modelling, and target engagement. Attendees heard from leading voices at GSK, Abbvie, Amphista, Autotac Bio, PhoreMost, and the University of Dundee, and connected with over 80 experts driving innovation across oncology, neurodegeneration, and immunology.
Whether you were focused on early discovery or clinical translation, this summit offered the insights and connections to accelerate your proximity pipeline.
Unmissable 2026 Event Highlights
Charting the Future of Proximity Therapeutics
Professor Ciulli opened the summit with a deep dive into the evolution of targeted protein degradation, sharing new insights into ternary complex formation and the next generation of proximity-based drug design.
Advancing Molecular Glue Mechanisms for Precision Targeting
You explored how molecular glues are being rationally designed to enhance selectivity and therapeutic potential, with cutting-edge research on degradation pathways and screening strategies.
Fuelling Innovation: VC & Pharma Perspectives on European TPD Growth
Attendees gained insider perspectives on how investors and pharma partners are backing proximity-based platforms, structuring collaborations, and identifying the next wave of clinical candidates.
Hands-On Learning Through Deep-Dive Workshops
You joined interactive sessions focused on antibody-based degraders, non-oncology applications, and glueable target identification to expand your modality toolkit.
Clinical Momentum: First-in-Human Data & Translational Insights
You heard exclusive updates from companies advancing proximity drugs into the clinic, with case studies on PK modelling, dosing strategies, and cross-species validation.
Explore the 2026 Full Event Guide
- 25+ Expert Speakers from Leading Biopharma and Academia
- 15+ Data-Led Case Studies Showcasing Clinical Updates, Novel Ligases, and Glue Discovery Breakthroughs
- 8+ Hours of Networking Including Speed Networking, Poster Sessions, and Informal Collaboration
- 3 Deep-Dive Workshops on Antibody-Based Degraders, Non-Oncology Applications, and Glueable Target Identification
Attending Companies Included
Explore the 2026 Agenda
Discover the latest breakthroughs in PROTACs, molecular glues, and proximity therapeutics through expert-led sessions and case studies.
Partner With Us In 2027
Connect with Europe's leading drug developers seeking discovery platforms, chemistry services, and translational support for TPD programs.
Join the TPD Community in 2027
Network with top scientists and biopharma innovators driving proximity-based drug development across oncology, CNS, and beyond.